Science keeps winning! Scientists recently transplanted a pig’s kidney into a human being without immediate rejection by the immune system.
A step in the right direction, the achievement could help ease the shortage of human organs for transplant by using animal organs.
Performed at the NYU Langone Health in New York City, the procedure used the kidney of a pig whose genes had been modified to get rid of a particular molecule which causes human immune systems to reject animal organs.
According to Reuters, the recipient of the pig kidney is a comatose patient who was experiencing kidney dysfunction. The subject’s family consented to the pig kidney transplantation before she was set to be taken off life support.
How was the procedure done?
In the pilot phase of the transplant, the pig kidney was attached to her blood vessels but kept outside the body. This gave researchers access to the kidney for three days in case things were to go awry.
The kidney function after the transplant appears to be normal so far. Turns out the kidney is also making as much urine as expected from a kidney. In fact, Dr. Robert Montgomery, the lead researcher of the study told Reuters that it’s working akin to a human kidney.
The most telling sign of the pig kidney working? The recipient’s kidney function has become normal again. Earlier, the subject’s creatinine levels were abnormal and now they appear stable.
Kidney shortage in India
Researchers across the globe have been working for decades to transplant animal kidneys into humans. Unfortunately, the immediate rejection has remained extremely high among recipients. With this new pig kidney transplant, things may be headed for a shake-up.
According to Narayana Health, almost 200,000 patients in India are awaiting organ donation with only 15,000 available donors. This gap could be filled with animal transplants modelled around this one.
Reference:
https://www.indiatimes.com/technology/science-and-future/pig-kidney-transplant-in-human-552148.html
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.
The global pharmaceutical fine chemicals sector is undergoing a profound transformation, with India emerging as a central growth engine amid sweeping changes in supply chain strategies and regulatory priorities. As drug makers and contract manufacturers adapt to stricter oversight and evolving sourcing preferences, the industry’s focus is shifting rapidly from cost efficiency to compliance, localisation and technical sophistication.
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.
We’re pleased to share an important milestone in our sustainability journey.
ExSyn has been awarded the EcoVadis Platinum Medal, placing us among the top 1% of companies globally evaluated for environmental, social and ethical performance.
While fears around a complete shutdown of the Strait of Hormuz primarily raise concerns around oil prices and energy security, recent history shows that even partial disruptions or security threats along key sea routes can quickly spill over into freight inflation, longer transit times and working capital stress for exporters and importers.
The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.
As we approach the close of this year, we at ExSyn would like to extend our heartfelt gratitude for your trust, collaboration, and continued support. Your confidence in our products and services has been the driving force behind our growth and success.
The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.
Products containing titanium dioxide in the EU are no longer required to carry warnings about cancer risk, after the European Chemicals Agency (Echa) revoked its classification as a suspected carcinogen. The move follows a June 2025 decision by the Court of Justice of the European Union and means that safety data sheets, labelling and packaging requirements for titanium dioxide have been relaxed across industries including paints, pharmaceuticals, cosmetics and food.